This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Multiple myeloma (MM)	Nuclear SET domain–containing protein 2 (NSD2; MMSET; WHSC1)	Mouse and cell culture studies suggest inhibiting NSD2 activity could help treat t(4;14)-translocated MM. t(4;14) translocations are found in about 10%–20% of MM cases and drive overexpression of NSD2 and fibroblast growth factor receptor 3 (FGFR3; CD333). In MM cell lines with the t(4;14) translocation, small hairpin RNA knockdown of *NSD2* decreased proliferation on and adherence to bone marrow stroma compared with no knockdown. In mice injected with MM cells that had doxycycline-inducible *NSD2* knockdown, doxycycline decreased tumorigenesis and disease progression compared with no treatment. Next steps could include developing inhibitors of NSD2. *SciBX* 6(39); doi:10.1038/scibx.2013.1090 Published online Oct. 10, 2013	Patent and licensing status undisclosed	Huang, Z. *et al. Cancer Res.*; published online Aug. 26, 2013; doi:10.1158/0008-5472.CAN-13-1000 **Contact:** Min Hu, Novartis Institutes for BioMedical Research, Shanghai, China e-mail: min.hu@novartis.com